Background: Superb microvascular imaging (SMI) is a new ultrasound vascular imaging technology, which uses a new Doppler algorithm, it has the characteristics of high sensitivity and high resolution to detect low velocity blood flow; it is easier to detect microvessels with low-velocity flow compared with color Doppler flow imaging in theory; and it can image the microvessels of the lesion without angiography.[1] Previous studies showed that SMI can detect tumor neovascularization to differentiate benign from malignant focal liver lessions (FLLs). However, the results of these studies have been contradictory with low sample sizes. This meta-analysis tested the hypothesis that SMI is accurate in distinguishing benign and malignant FLLs.
Methods: We will search PubMed, Web of Science, Cochrane Library, and Chinese biomedical databases from their inceptions to the November 30, 2020, without language restrictions. Two authors will independently carry out searching literature records, scanning titles and abstracts, full texts, collecting data, and assessing risk of bias. Review Manager 5.2 and Stata14.0 software will be used for data analysis.
Results: This systematic review will determine the accuracy of SMI in the differential diagnosis between benign and malignant FLLs.
Conclusion: Its findings will provide helpful evidence for the accuracy of SMI in the differential diagnosis between benign and malignant FLLs.
Systematic Review Registration: INPLASY2020120081.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837924 | PMC |
| http://dx.doi.org/10.1097/MD.0000000000024411 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hepatic Mesenchymal Hamartoma With Elevated Alpha-Fetoprotein: A Diagnostic Dilemma.
Cureus
November 2024
Pathology and Lab Medicine, All India Institute of Medical Sciences, Bhopal, Bhopal, IND.
Hepatic mesenchymal hamartoma (HMH) is an uncommon, benign liver tumor predominantly affecting children under three years of age. It is characterized histologically by disorganized mesenchymal stroma, abnormal bile ducts, blood vessels, and hepatocytes. HMH can present as a large cystic mass, a solid mass, or a combination of both.
View Article and Find Full Text PDFEstablishment of Biobank and Patient-Derived Xenograft of Soft Tissue and Bone Tumors.
Cureus
November 2024
Division of Musculoskeletal Oncology and Orthopaedics Surgery, Tochigi Cancer Center, Utsunomiya, JPN.
Soft tissue and bone tumors are rare, and their low frequency and diverse histological types make conducting large-scale clinical trials challenging. Patient-derived xenografts (PDX), entailing implantation of cancer specimens in immunocompromised mice, are emerging as a valuable translational model because PDX keeps the original tumors' character and drug sensitivity. We sequentially transplanted 166 surgical and biopsy specimens from orthopedic surgeries, including 138 soft tissue and bone tumors (81 malignant, 23 intermediate, and 34 benign), 16 metastatic bone tumors, 9 hematological malignancies, and 3 non-tumor tissues.
View Article and Find Full Text PDFEverolimus in pituitary tumor: a review of preclinical and clinical evidence.
Front Endocrinol (Lausanne)
December 2024
Department of Endocrinology and Metabolism, Lanzhou University Second Hospital, Lanzhou, Gansu, China.
Although pituitary tumors (PTs) are mostly benign, some PTs are characterized by low surgical resection rates, high recurrence rates, and poor response to conventional treatments and profoundly affect patients' quality of life. Everolimus (EVE) is the only FDA-approved mTOR inhibitor, which can be used for oral treatment. It effectively inhibits tumor cell proliferation and angiogenesis.
View Article and Find Full Text PDFProton therapy versus conventional radiotherapy for the treatment of cavernous sinus benign meningioma, a randomized controlled phase III study protocol (COG-PROTON-01).
BMC Cancer
December 2024
ISTCT UMR 6030-CNRS, Université de Caen-Normandie, Caen, 14000, France.
Background: Proton therapy (PRT) is an innovative radiotherapeutic modality for the treatment of cancer with unique ballistic properties. The depth-dose distribution of a proton beam reduces exposure of healthy tissues to radiations, compared with photon-therapy (XRT). To date, only few indications for proton-therapy, like pediatric cancers, chordomas, or intra-ocular neoplasms, are reimbursed by Health systems.
View Article and Find Full Text PDFDiagnostic Value of the Ovarian-Adnexal Reporting and Data System Ultrasound in Ovarian Masses: A Two-Center Study.
Br J Radiol
December 2024
Ultrasound Department, Fourth Affifiliated Hospital of Harbin Medical University, Surgeon's Hall, No. 37, Yiyuan Road, Nangang District, Harbin City, Heilongjiang prov, China.
Objective: This study aimed to assess the diagnostic efficacy of the Ovarian-Adnexal Reporting and Data System (O-RADS) and Ultrasound (US) and its sub-classification system for distinguishing ovarian masses.
Methods: O-RADS US was used for the retrospective analysis of 606 ovarian masses of Chinese from two medical centers by two gynecologic sonographers with varying experience. The O-RADS 4 categories masses were further sub-classified into O-RADS 4a and O-RADS 4 b through three different approaches(O-RADS A1/A2/A3).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!